Use of the ACE inhibitor zofenopril in the treatment of ischemic heart disease

Expert Review of Cardiovascular Therapy

Volumn 4, Issue 5, 2006, Pages 631-647

  Buikema, Hendrik ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiotensin converting enzyme inhibitors; Antioxidant; High tissue potency; Ischemic heart disease; Myocardial infarction; Sulfhydryl group; Zofenopril

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; BENAZEPRIL; BRADYKININ RECEPTOR; CAPTOPRIL; CILAZAPRIL; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; FOSINOPRILAT; HEMOGLOBIN; INTERCELLULAR ADHESION MOLECULE 1; LISINOPRIL; NITRIC OXIDE; PERINDOPRIL; QUINAPRIL; QUINAPRILAT; RAMIPRIL; RAMIPRILAT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SUPEROXIDE DISMUTASE; TRANDOLAPRIL; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ZOFENOPRIL; ZOFENOPRILAT;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; BLOOD CLOT LYSIS; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; STRUCTURE ANALYSIS; SURVIVAL RATE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIOXIDANTS; CAPTOPRIL; CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CHRONIC DISEASE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA;

EID: 33750960643     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.4.5.631     Document Type: Article

References (108)

1. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E. A review of the angiotensin-converting enzyme inhibitor, zofenopril, in the treatment of cardiovascular diseases. Expert Opin. Pharmacother. 5(9), 1965-1977 (2004).
2. Opie LH, Kowolik H. The discovery of captopril: large animals to small molecules. Cardiovas. Res. 30, 18-25 (1995).
3. Tigerstedt R, Bergman PG. Nierre and Kreislauf. Skand. Arch. Physiol. 8, 223-271 (1898).
4. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. The production of persistant elevation of systolic blood pressure by means of renal ischemia. J. Exp. Med. 59, 347-349 (1934).
5. Skeggs LT, Kahn JR, Shumway NP. The preparation and fucntion of the hypertension-converting enzyme. J. Exp. Med. 103, 295-299 (1956).
6. Ng KK, Vane JR. Conversion of angiotensin-I to angiotensin-II. Nature 218, 144-150 (1967).
7. Bakhle YS. Conversion of angiotensin-I to angiotensin-II by cell-free extracts of dog lung. Nature 220, 919-921(1968).
8. Ondetti MA, Rubin B, Cushman DW. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196(4288), 441-444 (1977).
9. Dzau VJ. Evolving concepts of the renin-angiotensin system. Focus on renal and vascular mechanisms. Am. J. Hypertens. 1, 334S-337S (1988).
10. Dzau VJ. Circulating versus local renin-angiotensin system in cardiovascular homeostasis. Circulation 7, 14-113 (1988).
11. Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am. J. Cardiol. 66(11), 22D-30D (1990).
12. Pines A, Fisman FZ. ACE inhibition with moexipril: a review of potential effects beyond blood pressure control. Am. J. Cardiovasc. Drugs 3(5), 351-60 (2003).
13. Gerstein HC. Cardiovascular and metabolic benefits of ACE-inhibition: moving beyond blood pressure reduction. Diabetes Care 23(7), 882-883 (2000).
14. Ross R, Glomset J, Harker L. Response to injury and atherogenesis. Am. J. Pathol. 86, 657-684 (1977).
15. Rosenfeld ME. Oxidized LDL affects multiple atherogenic cellular responses. Circulation 83, 2137-2140 (1991).
16. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle. Nature 288, 373-376 (1980).
17. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333, 664-666 (1988).
18. Goligorsky MS. Endothelial cell dysfunction: can't live with it, how to live without it. Am. J. Physiol. Ren. Physiol. 288, F871-F880 (2005).
19. Sumpio BE, Riley JT, Dardik A. Cells in focus: endothelial cell. Int. J. Biochem. Cell Biol. 34(12), 1508-1512 (2002).
20. McCord JM, Friclovich I. Superoxide dismutase. An enzymic fiinction for erythocuprein (hemocuprein). J. Biol. Chem. 244, 6049-6055 (1969).
21. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part I: basic mechanisms and in vivo monitoring of ROS. Circulation 108, 1912-1916 (2003).
22. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury. Part II: Animal and human studies. Circulation 108, 2034-2040 (2003).
23. Rathaus M, Bernheim J. Oxygen species in the mircovascular environment: regulation of vascular tone and the development of hypertension. Nephrol. Dial. Transplant 17, 216-221 (2002).
24. Fukai T, Folz RJ, Landmesser U, Harrison DG. Extracellular superoxide dismutase and cardiovascular disease. Cardiovasc. Res. 55, 239-249 (2002).
25. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 18, 65 5-637 (2000).
26. Soccio M, Toniato E, Evangelista V, Carluccio M, De Caterina R. Oxidative stress and cardiovascular risk. the role of vascular NAD(P)H oxidase and its genetic variants. Eur J. Clin. Invest 35(5), 305-314 (2005).
27. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NAD/NADPH oxidase activation: contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923 (1996).
28. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprtein in vascular smooth muscle cells. Circulation 95, 473-478 (1997).
29. Cushman DW, Cheung HS. Concentrations of angiotensin-converting enzyme in tissues of the rat. Biochim. Biophys. Acta. 250, 261-264 (1971).
30. Lee MA, Paul M, Bohm M, Ganten D. Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems Am. J. Cardiol 70(10), 12C-19C (1992).
31. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VJ. Tissue-specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ. Res. 69, 475-482 (1991).
32. Pinto YM, de Smet DG, van Gilst WH et al. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc. Res. 27(11), 1933-1938 (1993).
33. Grandi AM, Bignotti M, Gaudio G, Zanzi P, Guasti L, Venco A. Ambulatory blood pressure and left ventricular changes during antihypertensive treatment: perindopril versus isradipine, J. Cardiovasc. Pharmacol 26(5), 737-741 (1995).
34. Ferrari R. Effect of ACE inhibition on myocardial ischemia. Eur. Heart J. 19(Suppl. J), 737-741 (1998).
35. Johnston CI. Tissue angiotensin converting enzyme in cardiac and vascular hypertrophy, repair, and remodeling. Hypertension 28, 146-158 (1994).
36. Bernstein KE. The role of tissue angiotensin-converting enzyme (ACE), studies of (ACE), mutant mice. Am. J. Cardiol 82, 5S-7S (1998).
37. Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 16(5), 564-572 (1990).
38. Lee AF, MacFadyen RJ, Struthers AD. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study. Eur J. Heart Fail 1, 401-406 (1999).
39. Kromer EP, Riegger GA. Effects of long-term angiotensin converting enzyme inhibition on myocardial hypertrophy in experimental aortic stenosis in the rat. Am. J. Cardiol. 62, 161-163 (1988).
40. Bruckschlegel G, Holmer SR, Jandeleit K et al. Blockade of the renin-angiotensin system in cardiac pressure-overload hypertrophy in rats. Hypertension 25(2), 250-259 (1995).
41. Ruzicka M, Leenen FH. Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy. Circulation 91, 16-19 (1995).
42. Lear W, Ruzicka M, Leenen FH. ACE inhibitors and cardiac ACE mRNA in volume overload-induccd cardiac hypertrophy. Am. J. Physiol. 273, H641-H646 (1997).
43. Westendorp B, Schoemaker R, Buikema H, de Zeeuw D, van Veldhuisen DJ, van Gilst WH. Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with experimental myocardial infarction. JRAAS 5, 27-31 (2004).
44. Oosterga MA, Voors AA, Buikema H et al Angiotensin II formation in human vasculature after chronic ACE inhibition - a prospective, randomized placebo-controlled study. For the QUO VADIS investigators. Cardiovasc. Drugs Ther. 14, 55-60 (2000).
45. Buikema H, Pinto YM, van Geel PP et al. Preferential i,nhibition of angiotensin converting enzyme by utibapril. Biochemical and functional measurement of tissue specific ACE-inhibition. J. Cardiovasc. Pharmacol 29, 684-691 (1997).
46. Oosterga MA, Voors AA, Pinto YM et al. Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril. on Vascular Ace and Determinants of Ischemia. Am. J. Cardiol, 87(5), 542-546 (2001).
47. Dzau VJ, Berstein K, Celermajer D. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am. J. Cardiol 88(Suppl.), 1L-20L (2001).
48. Working group on tissue angiotensin converting enzyme, international society of cardiovascular pharmacotherapy. Pathophysiologic and therapeutic importance of tissue ACE: A consensus report. Cardiovasc. Drugs Ther. 16, 149-160 (2002).
49. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr. Med. Res. Opin 20(10), 1559-1569 (2004).
50. Ranadive SA, Chen AX, Serajuddin ATM. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 9, 1480-1486 (1992).
51. Hornig B, Arakawa N, Haussmann D, Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 98, 2242-2848 (1998).
52. PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart J. 24, 475-484 (2003).
53. Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
54. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multi-centre trial (the EUROPA study). Lancet 362, 782-788 (2003).
55. Pitt B, O'Neill B, Feldman R et al. The quinapril ischemic event trial (QUIET), Evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol. 87, 1058-1063 (2001).
56. The PEACE Trial Investigators. Angiotensin converting enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
57. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with perculiar cardioprotective properties. Cardiovasc. Drugs Rev. 17(2), 115-153 (1999).
58. Grover GJ, Sleph PG, Dzwonczyk S et al. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE-inhibitor and cardioprotection. J. Pharmacol Exp. Ther. 257, 919-929 (1991).
59. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am. J. Hypertens. 2(4), 294-306 (1989).
60. Sargent CA, Sleph PG, Dzwonczyk S et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J. Pharmacol Exp. Ther. 265, 609-618 (1993).
61. Liu X, Engelman RM, Ronson JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin-converting enzyme inhibitors. Cardiovasc. Drugs Ther. 6, 437-433 (1992).
62. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R. Cardioprotective effect of zofenopril in perfused rat heart subjected to ischemia and reperfusion. J. Cardiovasc. Pharmacol 43, 294-299 (2004).
63. Anning PB, Grocott-Mason RM, Lewis MJ. Effects of sulphydryl- and non-sulphydryl-containing ACE inhibitors on left ventricular relaxation in the isolated guinea pig heart. Endothelium 5, 265-275 (1997).
64. Van Gilst WH, Scholtens E, de Graeff PA. de Langen CDJ, Wesseling H. Difierential influences of angiotensin converting-enzyme inhibitors on the coronary circulation. Circulation 77, 124-129 (1988).
65. Sacco G, Bigioni M, Evangelista S, Goso C, Manzini S, Maggi CA. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubucin-induced cardiotoxicity in the rat. Eur. J. Pharmacol. 414, 71-78 (2001).
66. Pinto YM, van Wijngaarden J, van Gilst WH, de Graeff PA, Wesseling H. The effects of short- and long-term treatment with an ACE-inhibitor in rats with myocardial infarction. Basic Res. Cardiol 86(Suppl. 1), 165-172 (1991).
67. Van Wijngaarden J, Pinto YM, van Gilst WH, de Graeff PA, de Langen CDJ, Wesseling H. Converting enzyme inhibition after experimental myocardial infarction in rats: comparative study between spirapril and zofenopril. Cardiovasc. Res. 25, 936-942 (1991).
68. Przyklenk K, Kloner RA. Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by different mechanisms of action. Am. Heart J. 121(5), 1319-1330 (1991).
69. Przyklenk K, Kloner RA. 'Cardioprotection by ACE-inhibitors in acute myocardila ischemia and infarction? Basic Res. Cardiol 88(Suppl. 1), 139-154 (1993).
70. Westlin W, Mullane K. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals? Circulation 77(6 Pt 2), 130-139 (1988).
71. Chopra M, Beswick H, Clapperton M et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and antioxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J. Cardiovasc. Pharmacol. 19, 330-340 (1992).
72. Napoli C, Sica V, de Nigris F et al. Sulfhyryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am. Heart J. 148, e5 (2004).
73. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin converting enzyme inhibitor zofenopril. J. Int. Med. Res. 33, 42-54 (2005).
74. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative ttress in cardiovascular diseases. J. Hypertens. 18, 655-673 (2000).
75. Keany JF, Vita JA. Vascular oxidative stress and antioxidant protection in atherosclerosis. What do the clinical trials say? J. Cardiopulm. Rehab. 22, 225-253 (2002).
76. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 154-160 (2000).
77. Lonn EM, Yusuf S, Dzavik V et al. Effects of ramipril and vitamin E on atherosclerosis. The study to evalute carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103, 919-925 (2001).
78. Ceconi C, Boraso, A, Cargnoni A, Ferrari R. Oxidative stress in cardiovascular disease: myth or fact? Arch. Biochem. Biophys. 420, 217-221 (2003).
79. Buikema H, Monnink S, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH. Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br. J. Pharmacol, 130, 1999-2007 (2000).
80. Teerlink JR, Clozel M, Fischli W, Clozel JP. Temporal evolution of endothelial dysfunction in a rat model of chronic heart failure. J. Am. Coll. Cardiol, 22, 615-620 (1993).
81. Bauersachs J, Bouloumie A, Fraccerollo D, Hu K, Busse R, Ertl G. Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100, 292-298 (1999).
82. Mazor D, Golan E, Philip V et al. Red blood cell permeability to thiol compounds following oxidative stress. Eur. J. Haematol. 57, 241-246 (1996).
83. Swedberg K, Held P, Kjekhus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enelapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med. 327, 678-684 (1992).
84. Cohn-JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310 (1991).
85. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions an congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991).
86. Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trail. N. Engl. J. Med. 327, 669-677 (1992).
87. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, L821-828 (1993).
88. Kober L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandopril in patients with left ventncular dysfunction after myocardial infarction. Trandopril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333, 1670-1676(1995).
89. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3, effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular fimcdon after acute myocardial infarction. Lancet 343, 1115-1122 (1994).
90. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4, a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345, 668-685 (1995).
91. CCS-1. Oral Captopril versus placebo among 13634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 345, 686-687 (1995).
92. Maggioni AP. Secondary prevention: improving outcomes following myocardial infarction. Heart 84(Suppl. I), 15-17 (2000).
93. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in early treatment of acute myocardial infarction. Systematic overview of individual data from 100,000 patients in randomised trials. Ciculation 97, 2202-2212 (1998).
94. Ambrosioni E, Borghi C, Magnani B. Early treatment of acute myocardial infarction with angiotensin-convertingenzyme inhibition: safety considerations. SMILE pilot study working party. Am. J. Cardiol 68(14), 101D-110D (1991).
95. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators. N. Engl. J. Med. 332, 80-85 (1995).
96. Borghi C, Ambrosioni E, Magnani B. Effects of the early administration of zofenopril on onset and progression of congestive heart failure in patients with anterior wall acute myocardial infarction. The SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am. J. Cardiol. 78(3), 317-22 (1996).
97. Borghi C, Bacchelli S, Degli Esposti D, Ambrosioni E, on behalf of the SMILE Study Investigators. Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Am. J. Hypertens. 12(7), 665-672 (1999).
98. Borghi C, Bachelli S, Degli Esposti D, Ambrosioni E. Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with acute anterior myocardial infarction. Diabetes Care 26(6), 237-250 (2003).
99. Zuanetti G, Latini R, Magioni AP et al., for the GISSI-3 investigators. Effect of the ACE inhibitor lisinopril on mortality indiabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96, 4239-4245 (1997).
100. Borghi C, Ambrosioni E. In: Efficay of myocardial infarction therapy. Nash IS, Fuster V (Eds). Marcel Dekker, Inc, NY, USA, 237-250 (1999).
101. Borghi C, Ambrosioni E. Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am. Heart J. 145, 80-87 (2003).
102. de Kam PJ, van den Berg MP, Borghi C, Hochman JS, van Veldhuisen DJ, van Gilst WM. Acute administration of angiotensin converting enzyme inhibitors in thrombolysed myocardial infarction patients is associated with a decreased incidence of heart failure, but an increased re-infarction risk. Cardiovasc. Drugs Ther. 19(2), 119-124 (2005).
103. Borghi C, Ambrosioni E. Effects of zofenopril on ischemia following myocardial infarction: the SMILE study. J. Am. Coll, Cardiol 43(5, Suppl. A), 263A (2004) (Abstract).
104. Braun-Menendez E, Fasciolo, JC, Leloir, Munoz JM. The substance causing renal hypertension. J. Physiol. 98, 283-298 (1940).
105. Merril AJ, Morrison J, Brannon ES. Concentration of renin in renal venous blood of patients with chronic heart failure. Am. J. Med. 1, 468-472 (1946).
106. Burch GE. Evidence far increased venous tone in chronic congestive heart failure. Arch. Intern. Med. 98, 750-766 (1956).
107. Turini GA, Brunner HR, Gribic M, Waeber B, Gavras H. Improvement of chronic congestive heart failure by oral captoril. Lancet 1, 1213-1215 (1979).
108. CONSENSUS Trial Study Group. Effects of enapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalpril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).